Evidence map›Paper›PMID 26895969›Full record

SynthesisBMC complementary and alternative medicine2016

Effectiveness and safety of ShenXiong glucose injection for acute ischemic stroke: a systematic review and GRADE approach.

Xue-Ting Liu, Peng-Wei Ren, Le Peng, De-Ying Kang, Tian-le Zhang, Shu Wen, Qi Hong, Wen-Jie Yang

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in BMC complementary and alternative medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Frontiers in pharmacology · 2025
    Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Xue-Ting LiuDepartment of Evidence-based Medicine and Clinical Epidemiology, West China Hospital, Sichuan University, Chengdu, 610041, P. R. China.
Peng-Wei RenDepartment of Evidence-based Medicine and Clinical Epidemiology, West China Hospital, Sichuan University, Chengdu, 610041, P. R. China.
Le PengDepartment of Evidence-based Medicine and Clinical Epidemiology, West China Hospital, Sichuan University, Chengdu, 610041, P. R. China.
De-Ying KangDepartment of Evidence-based Medicine and Clinical Epidemiology, West China Hospital, Sichuan University, Chengdu, 610041, P. R. China. deyingkang@126.com.
Tian-le ZhangDepartment of Evidence-based Medicine and Clinical Epidemiology, West China Hospital, Sichuan University, Chengdu, 610041, P. R. China.
Shu WenDepartment of Evidence-based Medicine and Clinical Epidemiology, West China Hospital, Sichuan University, Chengdu, 610041, P. R. China.
Qi HongDepartment of Evidence-based Medicine and Clinical Epidemiology, West China Hospital, Sichuan University, Chengdu, 610041, P. R. China.
Wen-Jie YangDepartment of Evidence-based Medicine and Clinical Epidemiology, West China Hospital, Sichuan University, Chengdu, 610041, P. R. China.
Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo appraise critically whether published trials of ShenXiong glucose injection for patients with acute ischemic stroke (AIS) are of sufficient quality, and in addition to rate the quality of evidence by using the GRADE approach (grading of recommendations, assessment, development, and evaluation, GRADE).

methodsA literature search was performed in the Cochrane Library, MEDLINE, EMBASE, CBM, Chinese TCM (traditional Chinese medicine) Database, CNKI, VIP, WanFang Databases until January 2015. The limits were patients with AIS and randomized controlled trials (RCTs) or quasi-RCTs. Studies by which patients suffering intracerebral haemorrhage were excluded.

resultsTwelve studies fulfilled the inclusion criteria. We found significant benefits of ShenXiong glucose injection compared with conventional treatment in improving activities of daily living function at 4 weeks (MD = 34.12, 95 % CI: 29.07, 39.17), neurological function deficit at 2 weeks (MD = -5.39, 95% CI: -6.90, -3.87), 4 weeks (MD = -5.16, 95 % CI: -6.49, -3.83), and clinical effects at 4 weeks (RR = 1.17, 95% CI: 1.10, 1.24). No trials reported the effects of ShenXiong glucose injection on the risk of early, deterioration, or quality of life. No adverse events were reported within the whole follow-up period.

conclusionsThe use of ShenXiong glucose injection may improve rehabilitation for patients with acute ischemic stroke, however, as the GRADE approach indicated low to moderate quality of available evidence as well as insufficient information about harm and patients preference, the recommendations were not provided for ShenXiong glucose injection taking as a therapeutic intervention to patients with acute ischemic stroke.

Indexed as

Drugs, Chinese HerbalHumansStrokeDrugs, Chinese Herbalshenxiong glucose

Identifiers

PMID26895969
PMCPMC4761180
OpenAlexW2274269475

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.